Video

NCCN 2024 Prostate Cancer Guidelines Update VL

Search

2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, emphasizing the importance of confirming castrate status and proper staging. The presentation covers treatment options for adenocarcinoma and small cell/neuroendocrine variants, highlighting the signi...
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
NCCN 2024 Prostate Cancer Guidelines Update: Relugolix Gains Prominence in Treating Metastatic Castration-Sensitive Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen explore the significant updates to the 2024 NCCN guidelines for prostate cancer, focusing on the integration of relugolix for metastatic castration-sensitive prostate cancer (M1-CSPC). Dr. Sayyid highlights the HERO trial, which established relugolix as an effective oral GnRH antagonist with rapid and sustained testosterone suppression, outperforming leuprolide in b...
NCCN 2024 Prostate Cancer Guidelines Update: PARP Inhibitors in Focus - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines. They focus on non-hormonal systemic therapy, highlighting significant changes, particularly the emergence of PARP inhibitors like olaparib and rucaparib. The discussion covers their monotherapy and combination therapies, emphasizing the stronger endorsement for PARP inhibitors in patients with BRCA mut...
NCCN 2024 Prostate Cancer Guideline Updates: Progressive M0 CSPC Management - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen dive into the 2024 updates of the NCCN prostate cancer guidelines, specifically addressing the treatment and monitoring of progressive M0 CSPC in patients post-maximal pelvic therapy. Highlighting the critical nature of identifying high-risk patients, they introduce the major shift in recommendations based on the EMBARK trial results, which supports considering enza...
Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in prostate cancer management. This innovative test, now considered a predictive model, marks a significant advance, providing more accurate risk assessments for biochemical recurrence, distant metastasis, and prostate can...